Transplantation: Wherefore So Slight an Impact?

  • P. A. Keown
  • C. R. Stiller


The management of end stage renal disease (ESRD) has a major socioeconomic impact upon health care delivery in the Western world. Between 30 and 79 new cases per million population are accepted annually for care [1–3], this almost certainly reflecting an underestimate of the incidence of ESRD within the population [4]. Direct costs of such support have risen dramatically within the past decade, such that the expenditure on this therapy alone now exceeds 2 billion dollars annually in the United States.


Renal Transplantation Graft Survival Organ Donation Organ Retrieval Financial Disincentive 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kramer P, Broyer M, Brunner FP et al (1984) In: Davison AM (ed) Combined report on regular dialysis and transplantation in Europe XIV, 1983, vol 21Google Scholar
  2. 2.
    Posen G A (1984) All patients and facilities. Canadian renal failure register. The Kidney Foundation of Canada, p 5Google Scholar
  3. 3.
    Schmidt RW, Blumenkrantz M, Wiegmann TB (1983) The dilemmas of patient treatment for end stage renal disease. Am J Kidney Dis 3:37PubMedGoogle Scholar
  4. 4.
    Vital Statistics of the United States, vol 2, mortality part A (1965, 1966,1968)Google Scholar
  5. 5.
    Keown PA, Stiller CR (1986) Control of rejection of transplanted organs. In: Stollerman GH (ed) Advances in internal medicine. Yearbook Medical, Chicago, pp 17–46Google Scholar
  6. 6.
    Keown PA, Stiller CR, Wallace AC (1986) The nephrotoxicity of cyclosporine A. Kidney transplant rejection: diagnosis and treatment. Dekker, New York, pp 423–457Google Scholar
  7. 7.
    The Canadian Multicentre Transplant Study Group (1986) A randomized Clinical trial of cyclosporine in cadaveric renal transplantation. Analysis at three years. N Engl J Med 314:1219CrossRefGoogle Scholar
  8. 8.
    Sinclair NR, Jeffery JR, Keown PA, Stiller CR (1986) Risk factors and HLA Matching in renal transplantation using cyclosporine therapy. Transplant Proc (to be published)Google Scholar
  9. 9.
    Evans RW, Manninen DL, Garrison LP Jr., Hart LG et al (1985) The quality of life of patients with end stage renal disease. N Engl J Med 312:553PubMedCrossRefGoogle Scholar
  10. 10.
    Robinette MA, Marshall WJ, Arbus GS et al (1985) The donation process. Transplant Proc XVII:45Google Scholar
  11. 11.
    Bart KJ, Macon EJ, Whittier FC et al (1981) Cadaveric kidneys for transplantation: a paradox of shortage in the face of plenty. Transplantation 31:379PubMedCrossRefGoogle Scholar
  12. 12.
    Carlson D, Hellerstedt W, Anderson J et al (1985) Kidney donor candidacy study. Transplant Proc XVII: 99Google Scholar
  13. 13.
    Cardella CJ, DeVeber GA, Hollenberg C et al (1985) Donor identification. Transplant Proc XVII, 35Google Scholar
  14. 14.
    Hutchinson TA, Thomas DC, Lemieux JC et al (1984) Prognostically controlled comparison of dialysis and renal transplantation. Kidney Int 26:44PubMedCrossRefGoogle Scholar
  15. 15.
    Smith MD, Hong BA, Michelman JE (1983) Treatment bias in the management of end stage renal disease. Am J Kidney Dis 3:21PubMedGoogle Scholar
  16. 16.
    Robinette MA, Stiller CR (1985) Summary of task force recommendations. Transplant Proc XVII: 13Google Scholar
  17. 17.
    Keown PA, Stiller CR (1986) Dialysis or transplantation: an integrated approach to Management of end stage kidney disease. Kidney Int (to be published)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • P. A. Keown
  • C. R. Stiller

There are no affiliations available

Personalised recommendations